TY - JOUR
T1 - Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence
AU - van den Hout, Mari F. C. M.
AU - Koster, Bas D.
AU - Sluijter, Berbel J. R.
AU - Molenkamp, Barbara G.
AU - van de Ven, Rieneke
AU - van den Eertwegh, Alfons J. M.
AU - Scheper, Rik J.
AU - van Leeuwen, Paul A. M.
AU - van den Tol, M. Petrousjka
AU - de Gruijl, Tanja D.
PY - 2017/11
Y1 - 2017/11
N2 - Melanoma exerts immune-suppressive effects to facilitate tumor progression and metastatic spread. We studied these effects on dendritic cell (DC) and T-cell subsets in 36 melanoma sentinel lymph node (SLN) from 28 stage I-III melanoma patients and determined their clinical significance. Four conventional DC subsets, plasmacytoid DCs, and CD4(+), CD8(+), and regulatory T cells (Tregs), were analyzed by flow cytometry. We correlated these data to clinical parameters and determined their effect on local and distant melanoma recurrence, with a median follow-up of 75 months. In stage I and II melanoma, increased Breslow thickness (i.e., invasion depth of the primary melanoma) was associated with progressive suppression of skin-derived migratory CD1a(+) DC subsets. In contrast, LN-resident DC subsets and T cells were only affected once metas-tasis to the SLN had occurred. In stage III patients, increased CD4: CD8 ratios in concert with the accumulation of Tregs resulted in decreased CD8: Treg ratios. On follow-up, lower frequencies of migratory DC subsets proved related to local melanoma recurrence, whereas reduced maturation of LN-resident DC subsets was associated with distant recurrence and melanoma-specific survival. In conclusion, melanoma-mediated suppression of migratory DC subsets in the SLN precedes local spread, whereas suppression of LN-resident DC subsets follows regional spread and precedes further melanoma dissemination to distant sites. This study offers a rationale to target migratory as well as LN-resident DC subsets for early immunotherapeutic interventions to prevent melanoma recurrence and spread. (C) 2017 AACR.
AB - Melanoma exerts immune-suppressive effects to facilitate tumor progression and metastatic spread. We studied these effects on dendritic cell (DC) and T-cell subsets in 36 melanoma sentinel lymph node (SLN) from 28 stage I-III melanoma patients and determined their clinical significance. Four conventional DC subsets, plasmacytoid DCs, and CD4(+), CD8(+), and regulatory T cells (Tregs), were analyzed by flow cytometry. We correlated these data to clinical parameters and determined their effect on local and distant melanoma recurrence, with a median follow-up of 75 months. In stage I and II melanoma, increased Breslow thickness (i.e., invasion depth of the primary melanoma) was associated with progressive suppression of skin-derived migratory CD1a(+) DC subsets. In contrast, LN-resident DC subsets and T cells were only affected once metas-tasis to the SLN had occurred. In stage III patients, increased CD4: CD8 ratios in concert with the accumulation of Tregs resulted in decreased CD8: Treg ratios. On follow-up, lower frequencies of migratory DC subsets proved related to local melanoma recurrence, whereas reduced maturation of LN-resident DC subsets was associated with distant recurrence and melanoma-specific survival. In conclusion, melanoma-mediated suppression of migratory DC subsets in the SLN precedes local spread, whereas suppression of LN-resident DC subsets follows regional spread and precedes further melanoma dissemination to distant sites. This study offers a rationale to target migratory as well as LN-resident DC subsets for early immunotherapeutic interventions to prevent melanoma recurrence and spread. (C) 2017 AACR.
KW - REGULATORY T-CELLS
KW - DENDRITIC CELLS
KW - INDOLEAMINE 2,3-DIOXYGENASE
KW - METASTATIC MELANOMA
KW - FUNCTIONAL-ANALYSIS
KW - TUMOR BURDEN
KW - IMMUNE
KW - SKIN
KW - ACCUMULATION
KW - MULTICENTER
U2 - 10.1158/2326-6066.CIR-17-0110
DO - 10.1158/2326-6066.CIR-17-0110
M3 - Article
C2 - 28935649
SN - 2326-6066
VL - 5
SP - 969
EP - 977
JO - Cancer immunology research
JF - Cancer immunology research
IS - 11
ER -